Over four years after Gov. Phil Bryant signed Harper Grace’s Law, allowing clinical trials of a specific marijuana-derived drug, the University of Mississippi Medical Center announced Thursday that those trials had begun.
The trial, which will study the effect of cannabidiol or CBD, as it is better known, on children with severe epilepsy, is the very first university-based clinical trial of a cannabis extract to meet federal standards.
Sativa Investments (NEX:SATI) is the UK’s first medicinal cannabis investment vehicle. After investing in two North American businesses, it is now progressing a UK seed to consumer investment strategy with 100% ownership of businesses involved in the production, testing and compliance, research & development including pharmacology, commercialisation and sales & marketing of medicinal cannabis and cannabidiol products. Two UK businesses, George Botanicals and PhytoVista Laboratories, are already fully operational. The Company intends to add a 7.5-acre cannabis growing and processing facility and has already executed an option agreement over an optimum site.